Real-World Results For GLP-1 Drugs Underwhelm, Study Says

A new study in the journal *Obesity* indicates that real-world weight loss results for GLP-1 drugs like Ozempic, Wegovy, and Zepbound are less significant than those reported in clinical trials, with patients experiencing an average weight loss of under 9% after one year compared to the 15%-21% reported in trials. The study, tracking nearly 7,900 Cleveland Clinic patients, found that early treatment discontinuation and lower dosages were contributing factors to the reduced effectiveness; patients who remained on medication and received higher doses experienced more substantial weight loss, particularly with tirzepatide. Cost, insurance issues, side effects, and medication shortages were cited as common reasons for discontinuing treatment, impacting both weight and glycemic control, especially for patients with prediabetes.

Analysis

A new Cleveland Clinic study published in the journal *Obesity* reveals that real-world weight loss outcomes for GLP-1 drugs, including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Zepbound), are substantially less impressive than clinical trial results. Patients in a real-world setting lost an average of just under 9% of their body weight after one year, compared to the 15% to 21% efficacy reported in trials. This disparity is linked to high rates of treatment discontinuation and the prevalence of lower prescribed dosages, with 81% of nearly 7,900 patients studied receiving a low maintenance dose. Weight loss was significantly impacted by adherence: less than 4% for early discontinuers, versus 12% for those who persisted with treatment. Notably, patients on high doses of tirzepatide achieved 18% weight loss, and those on high-dose semaglutide achieved nearly 14%. Common reasons for cessation include cost, insurance issues, side effects, and medication shortages. The study also highlighted the crucial role of adherence in managing comorbidities, as 68% of prediabetic patients who stayed on GLP-1 treatment achieved normal blood sugar levels, a significantly better outcome than for those who discontinued. These findings suggest that the widespread adoption and ultimate market size for these blockbuster drugs may face headwinds from real-world patient behavior and access challenges, aligning with the provided moderately negative sentiment signal.

Key Decisions for Investors

• Investors should temper expectations regarding the peak sales potential of GLP-1 drugs, considering the reported gap between clinical trial efficacy and real-world outcomes driven by adherence and dosage issues.
• Closely monitor patient persistence rates, prescription dosage trends, and payer reimbursement dynamics, as these factors will be critical determinants of sustained revenue for GLP-1 drug manufacturers.
• Evaluate companies in the GLP-1 space based on their strategies to mitigate treatment discontinuation, such as addressing affordability, managing side effects, or developing formulations that improve adherence.
• Consider that the differentiation between GLP-1 products may increasingly depend on demonstrated real-world effectiveness and tolerability, beyond initial clinical trial data, particularly in light of the cautious tone indicated by market signals.